G. V. Hazel

发表

Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer

D. Goldstein, N. Spry, M. Michael, 2007, British Journal of Cancer.

Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer

V. Gebski, P. Gibbs, Ricky A. Sharma, 2017, JMIR research protocols.

Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.

V. Gebski, G. van Hazel, J. Anderson, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

R. Simes, A. Broad, V. Ganju, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.

A. Musk, N. de Klerk, J. Dewar, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab for the treatment of colorectal cancer.

Dongsheng Tu, John R Zalcberg, R. Simes, 2007, The New England journal of medicine.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

M. Stockler, V. Gebski, J. Zalcberg, 2010, British Journal of Cancer.

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

E. Van Cutsem, Y. Humblet, G. Bodoky, 2007, British Journal of Cancer.

Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial

P. Gibbs, W. Bechstein, V. Donckier, 2019, The British journal of surgery.

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

V. Gebski, J. Simes, D. Cunningham, 2015, British Journal of Cancer.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

W. Scheithauer, J. Zaluski, H. Burris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

D. Kerr, E. Van Cutsem, D. Cunningham, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

E. Van Cutsem, E. Raymond, A. Vinik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial.

W. Scheithauer, C. Twelves, J. Cassidy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non‐small cell lung cancer

J. Dewar, N. Spry, G. van Hazel, 2005, Internal medicine journal.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.

A. Musk, J. Upham, G. van Hazel, 1993, Australian and New Zealand journal of medicine.